Comparative Pharmacology
Head-to-head clinical analysis: DONEPEZIL HYDROCHLORIDE versus RAZADYNE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DONEPEZIL HYDROCHLORIDE versus RAZADYNE.
DONEPEZIL HYDROCHLORIDE vs RAZADYNE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible inhibitor of acetylcholinesterase, increasing acetylcholine concentration in the synaptic cleft of the central nervous system.
Galantamine is a reversible competitive acetylcholinesterase inhibitor and an allosteric modulator of nicotinic acetylcholine receptors, enhancing cholinergic function in the central nervous system.
Alzheimer's disease: Initial 5 mg orally once daily at bedtime for 4-6 weeks, increase to 10 mg once daily. Maximum dose 10 mg/day.
Initial dose 8 mg/day PO (4 mg twice daily) for 4 weeks; increase to 16 mg/day (8 mg twice daily) for at least 4 weeks; maintenance 16-24 mg/day (12 mg twice daily). Extended-release: initial 8 mg PO once daily; after 4 weeks increase to 16 mg once daily; if tolerated, may increase to 24 mg once daily.
None Documented
None Documented
Terminal elimination half-life approximately 70 hours (range 50-100 hours), allowing once-daily dosing; steady-state reached in 14-21 days
Terminal elimination half-life is approximately 7-8 hours in healthy adults, allowing twice-daily dosing; unchanged in mild to moderate hepatic impairment but prolonged in severe hepatic impairment.
Renal (26% unchanged), fecal (57%, primarily as metabolites via biliary excretion)
Renal excretion of unchanged drug accounts for approximately 20-25% of the dose; the remainder is metabolized by the liver and excreted as metabolites in urine (about 95% total) and feces (about 5%).
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor